Immuno-Oncology Program

This course has been reviewed and updated since its original publication date of December 2015.

The Immuno-Oncology program is designed to help the busy clinician keep on top of the rapidly developing field of immunotherapy as it relates to oncology.  The program address a wide variety of topics including cancer immunobiology, classes of agents, potential predictive biomarkers, clinical activity in the areas of melanoma and non-small cell lung cancer, response determination and the management of immune-related adverse events. 

Learning Objectives

  • Describe the components of the normal human immune system and their role in surveillance and anti-tumor activity
  • Identify  the mechanisms by which cancer vaccines may induce specific immunity to cancer
  • Examine other potential biomarkers of benefit to immune checkpoint blockade
  • Identify the immune modulating agents that have been used in the clinic
  • Apply RECIST-based response assessments to patients receiving cancer immunotherapy in the clinic
  • Describe management strategies for the toxicities associated with immunotherapies

Continuing Education Credit

8 Credits/Points are available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits
  • MOC Points:
    ABIM MOC Points
    ABMS (ABAI, ABPath, ABR, ABU) MOC Points
  • CNE Contact Hours
  • ONCC ILNA Points in Treatment Modalities and Symptom Management
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted. 
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on May 18, 2020. Participants must complete all necessary course components by this date to receive credit.